PTN

Insider Trades

Name	Value	Action	Price	Current Price
Wills Stephen TExecutive VP And CFO/COO $9.5k565 shares SellDec 24, 2025 $16.74 --
Dunton Alan WDirector $4.0M200 shares BuyJun 13, 2025 $20,000.00 --
Spana CarlDirector, Officer: President And CEO $225M1.5k shares BuyJun 13, 2025 $150,000.00 --
Wills Stephen TExecutive VP And CFO/COO $225M1.5k shares BuyJun 13, 2025 $150,000.00 --
Spana CarlDirector, Officer: President And CEO $300k2.7M shares BuyJun 13, 2025 $0.11 --
Wills Stephen TExecutive VP And CFO/COO $300k2.7M shares BuyJun 13, 2025 $0.11 --

News

prnewswire.comPalatin to Begin Trading on Nasdaq Stock Exchangeprnewswire.comMay 18

seekingalpha.comPalatin Technologies, Inc. (PTN) Q3 2026 Earnings Call Transcriptseekingalpha.comMay 13

prnewswire.comPalatin Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Updateprnewswire.comMay 13

Trade PTN

About Palatin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical firm specializing in the creation of precise, receptor-targeting treatments for various medical conditions throughout the United States. Its flagship product is Vyleesi, a melanocortin receptor (MCr) agonist prescribed for premenopausal women experiencing hypoactive sexual desire disorder. The company's pipeline also includes oral PL8177, a selective MC1r agonist peptide that has successfully concluded Phase I clinical trials for inflammatory bowel diseases. Additionally, Palatin is advancing PL9643, a peptide melanocortin agonist that engages multiple MCr, including MC1r and MC5r, intended for anti-inflammatory ocular conditions such as dry eye disease. It is also developing other melanocortin peptides to address diabetic retinopathy. In the cardiovascular realm, the firm is pursuing PL3994, an NPR-A agonist and synthetic analogue of the endogenous neuropeptide hormone atrial natriuretic peptide. A further compound, PL5028, acts as an NPR-A and NPR-binder, designed to tackle cardiovascular and fibrotic disorders, notably by mitigating cardiac hypertrophy and fibrosis. Established in 1986, the company maintains its principal operations in Cranbury, New Jersey.

CEO: Carl Spana
IPO Date: Oct 15, 1997

Market Data

Open: $11.92
High: $12.21
Low: $11.65
Volume: 9.5K
Avg Volume: 1.8M
52W High: $31.00
52W Low: $5.00

Valuation

Market Cap: $305M
Enterprise Value: $295M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-21M
Revenue: $0
Net Income: $-17M
Cash: $2.6M
Debt: $164k

Events

EarningsSep 2

EPS est. -1.2